Psyence Biomedical Ltd. acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder (PTSD), addiction, and other serious neurological and mental health conditions. The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therapies, particularly in areas where current treatment options ...

Psyence Biomedical Ltd. announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company as it prepares for the clinical development of ibogaine for substance use disorders and validates its investment in PsyLabs. This collaboration with PsyLabs is an important step in securing a long-term supply ...